HCG

Heterodimeric glycoprotein reference material · source, glycoform and bioactivity must be lot-defined

≥ 99.0% · target, verify batch COACAS 9002-61-3RUO

Research statusExtensively characterized endogenous hormone; this catalogue material is RUO and is not an FDA-approved finished drug reference context · supplied material is RUO

Supplied formGlycoprotein hormone (heterodimeric, non-covalent alpha/beta subunit assembly)

Lead time21–45 days

HCG — Lot- and formulation-specific material; do not infer urinary, recombinant, lyophilized or solution presentation from the name alone

HCG — Lot- and formulation-specific material; do not infer urinary, recombinant, lyophilized or solution presentation from the name alone · Representative packaging image · verify the ordered lot

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Research value includes LHCGR signalling, glycoprotein bioassay development, urinary-versus-recombinant comparability, glycan/charge-variant characterization, alpha/beta assembly, process-impurity methods and anti-doping reference work
These are laboratory contexts, not fertility, TRT/PCT, bodybuilding or weight-loss recommendations.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 9002-61-3
Formula: Not applicable — glycoprotein composition varies by glycoform and source
Molecular weight: Approximately 36.7–37.9 kDa
Appearance: Lot- and formulation-specific material; do not infer urinary, recombinant, lyophilized or solution presentation from the name alone
Purity: ≥ 99.0% · target, verify batch COA
Storage: Store and ship according to the released-lot COA and validated stability data for the exact urinary or recombinant source, glycoform profile, formulation, container, temperature and physical state. Pregnyl and Ovidrel have different presentations and label conditions; neither label establishes storage or post-reconstitution dating for an RUO lot.
MOQ: On request
Lead time: 21–45 days

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about HCG

Human chorionic gonadotropin (hCG) is a placental, non-covalent alpha/beta heterodimeric glycoprotein hormone. The mature alpha subunit is shared with LH, FSH and TSH, while the beta subunit and its glycosylated C-terminal extension contribute hCG specificity and prolonged exposure. Urinary-derived hCG and recombinant choriogonadotropin alfa differ in manufacturing source, glycoform distribution, impurity controls, presentation and regulatory identity. Named prescription products have product-specific approvals; this independently supplied material is an RUO reference/research reagent and must not inherit their indications, routes, sterility or storage claims.

Evidence contexts include LHCGR biology, endocrine bioassays, glycoform and source comparability, process analytics and anti-doping detection
FDA-approved indications belong to named prescription finished drugs
FDA states there are no approved hCG products for weight loss
This RUO material has no clinical indication.

Mechanism context

The question the literature is testing

Intact bioactive hCG binds the LH/hCG receptor (LHCGR), a GPCR expressed in reproductive endocrine tissues, and activates downstream signalling including cAMP-dependent pathways. Biological activity depends on correct alpha/beta assembly and glycosylation as well as amino-acid sequence. Findings from an approved finished drug or one glycoform distribution cannot be transferred automatically to another source or independently supplied lot.

Evidence map

Research routes and exposure context

Evidence tierApproved finished-product context

Research areaHormonal research

Routes reported in sources

No administration route applies

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

This catalogue material is not an approved sterile medicine
Finished hCG drug labels contain product- and population-specific risks, including ovarian hyperstimulation with fertility treatment, but those labels do not establish quality or safety of an RUO lot
FDA states hCG is not approved for weight loss and has not been shown to increase weight loss; severe calorie restriction carries serious risks
Chorionic gonadotrophin is prohibited in male athletes under the 2026 WADA Prohibited List

Interactions reported in the literature

No clinical combination or stacking guidance applies
Interactions or coordinated timing described in fertility labels, TRT practice, PCT or bodybuilding sources were removed
Combination experiments require a prespecified laboratory protocol, controls and risk review.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

HCG factory batch COAs

HCG 1000 IU Factory batch COA protected preview

HCG1000 IU · WHJLP-HCG1-260319-C

HCG 2000 IU Factory batch COA protected preview

HCG2000 IU · WHJLP-HCG2-260319-C

HCG 5000 IU Factory batch COA protected preview

HCG5000 IU · WHJLP-HCG5-260319-C

HCG 10000 IU Factory batch COA protected preview

HCG10000 IU · WHJLP-HCG10K-260318-C

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

Appearance alone cannot establish hCG identity, alpha/beta assembly, glycoform distribution, potency, purity or sterility
Require source and platform, orthogonal subunit and assembled-hormone identity, quantitative protein content, potency in IU with named reference and method, chromatographic/electrophoretic purity, glycan or charge-variant profile, aggregates and source-specific process impurities
Specify endotoxin, bioburden, sterility and particulates separately where required
An IU claim without method and reference or a mass claim without specific activity is incomplete.

Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

HCG-01KIU1,000 IU10 vials

HCG-02KIU2,000 IU10 vials

HCG-05KIU5,000 IU10 vials

HCG-10KIU10,000 IU10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Store and ship according to the released-lot COA and validated stability data for the exact urinary or recombinant source, glycoform profile, formulation, container, temperature and physical state. Pregnyl and Ovidrel have different presentations and label conditions; neither label establishes storage or post-reconstitution dating for an RUO lot.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Regulatory and product boundaries were checked against the current DailyMed labels for Pregnyl and Ovidrel, FDA HCG weight-loss Q&A, and the official 2026 WADA Prohibited List. Molecular biology is supported by the original beta-subunit literature and authoritative glycoprotein references. Label pharmacokinetics, storage and indications remain attached to the named finished product and are not transferred to this RUO material.

01
hCG: Biological Functions and Clinical Applications
International Journal of Molecular Sciences · 2017 · peer-reviewed review article
Open source
02
Human Chorionic Gonadotropin and Early Embryogenesis: Review
International Journal of Molecular Sciences · 2022 · peer-reviewed review article
Open source
03
Concomitant Intramuscular Human Chorionic Gonadotropin Preserves Spermatogenesis in Men Undergoing Testosterone Replacement Therapy
Journal of Urology · 2013 · peer-reviewed original research (retrospective cohort)
Open source
04
Efficacy and safety of human chorionic gonadotropin for treatment of cryptorchidism: A meta-analysis of randomised controlled trials
Journal of Paediatrics and Child Health · 2018 · systematic review / meta-analysis of randomized controlled trials
Open source
05
The Safety of Human Chorionic Gonadotropin Monotherapy Among Men With Previous Exogenous Testosterone Use
Cureus · 2022 · peer-reviewed original research (retrospective cohort)
Open source
06
Prevention of moderate and severe ovarian hyperstimulation syndrome: a guideline
Fertility and Sterility · 2024 · clinical practice guideline (professional society)
Open source
07
NOVAREL (chorionic gonadotropin) for injection — FDA-approved prescribing information
FDA / DailyMed (National Library of Medicine) · 2023 · regulatory document (FDA-approved drug label)
Open source
08
Questions and Answers on HCG Products for Weight Loss
U.S. Food and Drug Administration · 2016 · regulatory document (FDA consumer guidance)
Open source

Product FAQ

Questions buyers ask about HCG

Why are both IU and mass reported for hCG, and is there a universal conversion?+

IU describes biological activity assigned against a named reference and method; mass describes material quantity. Glycosylation, source, aggregation, degradation and assay design can change specific activity, so no catalogue-wide IU-per-mg conversion should be assumed. The quotation and COA should state the bioassay, reference standard, activity result, mass or protein assay and whether the value applies to urinary-derived or recombinant material.

How do urinary-derived and recombinant hCG differ for procurement?+

They share the hCG protein concept but differ in source, glycoform distribution, process-related impurities, formulation, regulatory identity and potentially specific activity. An approved urinary or recombinant finished-drug label cannot qualify an independently supplied RUO lot. Specify source, alpha/beta identity, glycosylation or charge-profile expectations, activity method and relevant impurity limits before purchase.

What should a decision-ready hCG batch package include?+

Request source and manufacturing platform, alpha/beta-subunit or orthogonal identity, intact/assembled and subunit characterization, chromatographic or electrophoretic purity, quantitative protein content, potency in IU using a named method and standard, glycan or charge-variant controls, aggregates, water and process-related impurities. Endotoxin, bioburden, sterility and particulates must be separately specified when required; chemical purity or IU activity alone does not establish an injectable medicine.

HCG

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about HCG

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

HCG factory batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Storage in the lab and temperature during transit are different decisions

Terms to settle before the purchase order

Literature behind the research context

hCG: Biological Functions and Clinical Applications

Human Chorionic Gonadotropin and Early Embryogenesis: Review

Concomitant Intramuscular Human Chorionic Gonadotropin Preserves Spermatogenesis in Men Undergoing Testosterone Replacement Therapy

Efficacy and safety of human chorionic gonadotropin for treatment of cryptorchidism: A meta-analysis of randomised controlled trials

The Safety of Human Chorionic Gonadotropin Monotherapy Among Men With Previous Exogenous Testosterone Use

Prevention of moderate and severe ovarian hyperstimulation syndrome: a guideline

NOVAREL (chorionic gonadotropin) for injection — FDA-approved prescribing information

Questions and Answers on HCG Products for Weight Loss

Questions buyers ask about HCG

Compare adjacent molecules and documentation needs.

Menotropins (HMG)

Oxytocin Acetate

ACTH (1-39)

Gonadorelin Acetate